Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
23
Participants
Timeline
Start Date
June 30, 2013
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
Conditions
Hepatic ImpairmentHealthy
Interventions
DRUG
lumacaftor 200 mg q12h + ivacaftor 250 mg q12h
Trial Locations (2)
Unknown
Prague
Bratislava
All Listed Sponsors
lead
Vertex Pharmaceuticals Incorporated
INDUSTRY
NCT01888393 - Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects | Biotech Hunter | Biotech Hunter